Figure 3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Year: 2026
Type: other
Abstract: Patient outcomes by baseline ctDNA and molecular response (post hoc analyses). A, PFS Kaplan–Meier curves for the BEP1 stratified by baseline ctDNA. B, PFS treatment responses in patients stratified by baseline ctDNA level, adjusted for PD-L1 and HPV status. C, PFS Kaplan–Meier curves for the BEP2 stratified by molecular responder status at week 15. D, BOR distribution across treatment groups. BEP1 is defined as all patients with a baseline sample, and the BEP2 is defined as all patients with both a baseline and week 15 sample. ctDNA high and low are defined as mVAF ≥ 1.33% and <1.33%, respectively. Molecular responders and nonresponders are defined as patients with a reduction from baseline at week 15 in ctDNA of ≥50% and <50%, respectively. AIC, Akaike information criterion; BOR, best overall response; MNR, molecular nonresponder; MR, molecular responder; PD, progressive disease; SD, stable disease.
Authors: Danny Rischin, Aaron R. Hansen, Ezra E.W. Cohen, Makoto Tahara, Kevin J. Harrington, Robert I. Haddad, Lisa Licitra, Hisham Mehanna, Robert L. Ferris, Piotr Koralewski, Konstantin Penkov, Michael Schenker, David R. Spigel, Amaury Daste, Min Hee Hong, Ye Guo, Michael J. Chisamore, Michael L. Washburn, Amy Phillips‐Jones, John Russell, Sumita Roy‐Ghanta, Catherine Ellis, Marc Ballas, Christophe Le Tourneau
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7137369132